Lexicon Pharmaceuticals, Inc.
1.3300-0.04 (-2.92%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · LXRX · USD
Key Stats
Market Cap
483.32MP/E (TTM)
-Basic EPS (TTM)
-0.32Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Lexicon Pharmaceuticals swung to an operating profit of $3.7 million in Q2 FY2025 ended June 30, 2025, up from a $55.4 million loss a year earlier, fueled by $27.5 million in licensing revenue from its Novo Nordisk deal for LX9851—while net product revenue dipped 18% y/y to $1.3 million. Total revenues soared 1,652% y/y to $28.9 million, yet YTD through six months showed a $22.0 million net loss, or $0.06 per diluted share on 362,687 weighted shares, consistent with no anti-dilution effects. R&D expenses fell 11% y/y to $15.7 million amid lower clinical costs, and SG&A plunged 76% y/y to $9.4 million post-restructuring. Cash and equivalents stood at $21.4 million with $117.6 million in short-term investments, after repaying $45 million on Oxford term loans now at $56.1 million (11.9% weighted rate, maturing 2029) and maintaining $29 million restricted cash for covenants. Free cash flow wasn't disclosed in the 10-Q. Licensing deals like Novo Nordisk's $45 million upfront buoyed liquidity, but clinical trial delays pose a key risk.
8-K
Q2 profit from licensing surge
Lexicon Pharmaceuticals swung to a $3.3 million net income in Q2 2025, fueled by $27.5 million in licensing revenue from its Novo Nordisk deal for LX9851, while INPEFA sales added $1.3 million. Partnership talks for pilavapadin advance post-Phase 2b data, with full results due in September; SONATA Phase 3 enrollment accelerates across 100+ sites for sotagliflozin in HCM. Cash dipped to $139 million amid severance costs. Progress sharpens R&D focus.
8-K
Nasdaq grants bid price extension
Lexicon Pharmaceuticals received Nasdaq's approval on July 3, 2025, for a 180-day extension until December 30 to meet the $1 minimum bid price rule, after transferring its common stock from the Global Select Market to the Capital Market effective July 7. The company plans a reverse stock split if needed to cure the deficiency. This buys time amid ongoing compliance pressures. Yet compliance hinges on market value and other listing standards.
8-K
Stockholders approve equity expansions
Lexicon Pharmaceuticals' stockholders approved amendments on June 2, 2025, boosting the 2017 Equity Incentive Plan's share pool from 55 million to 75 million shares and the Non-Employee Directors' plan from 2 million to 4 million, enabling more equity awards for employees and directors. They also greenlit a potential reverse stock split at 1-for-10 to 1-for-50 ratios before the 2026 meeting, giving the board flexibility to adjust share count. This bolsters talent retention amid biotech pressures. Equity pools expanded sharply.
AMLX
Amylyx Pharmaceuticals, Inc.
13.89-0.43
BLRX
BioLineRx Ltd.
3.50-0.18
CPRX
Catalyst Pharmaceuticals, Inc.
21.01-0.35
LBRX
LB Pharmaceuticals Inc
15.65-0.92
LEXX
Lexaria Bioscience Corp.
0.96+0.01
LXEO
Lexeo Therapeutics, Inc.
9.91-0.17
SCPH
scPharmaceuticals Inc.
5.67+0.00
SLXN
Silexion Therapeutics Corp
3.44+0.01
VRTX
Vertex Pharmaceuticals Incorpor
417.21-5.18
XRTX
XORTX Therapeutics Inc.
0.65+0.02